Literature DB >> 8010453

Adenosine produces pulmonary vasodilation in the perfused rabbit lung via an adenosine A2 receptor.

R G Pearl1.   

Abstract

Adenosine is a potent pulmonary vasodilator that has been used in therapy for clinical and experimental pulmonary hypertension. To determine the receptor responsible for adenosine-induced pulmonary vasodilation, we studied the relative potency of four adenosine agonists in the isolated buffer-perfused rabbit lung during pulmonary hypertension due to infusion of the thromboxane A2 mimetic U46619. The ED50 values for pulmonary vasodilation were 1.9 x 10(-8) mol/L for 5'-N-ethylcarboxamidoadenosine (NECA), 4.5 x 10(-8) mol/L for 2-phenylaminoadenosine (CV-1808), 2.6 x 10(-6) mol/L for R(-)-N6-(2-phenylisopropyl) adenosine (R-PIA), and 6.5 x 10(-6) mol/L for cyclopentyladenosine, results consistent with an adenosine A2 receptor. Pretreatment with the adenosine A1 receptor antagonist cyclopentyltheophylline did not affect the dose-response curve to NECA, and pretreatment with the adenosine A2 receptor antagonist CGS 15943A increased the ED50 of NECA to 2.7 x 10(-7) mol/L. These results suggest that adenosine produces pulmonary vasodilation via activation of an adenosine A2 receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8010453     DOI: 10.1213/00000539-199407000-00010

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice.

Authors:  Mohammed A Nayeem; Samuel M Poloyac; John R Falck; Darryl C Zeldin; Catherine Ledent; Dovenia S Ponnoth; Habib R Ansari; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-19       Impact factor: 4.733

2.  A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease.

Authors:  Ankit A Desai; Tong Zhou; Homaa Ahmad; Wei Zhang; Wenbo Mu; Sharon Trevino; Michael S Wade; Nalini Raghavachari; Gregory J Kato; Marlene H Peters-Lawrence; Tejas Thiruvoipati; Kristin Turner; Nicole Artz; Yong Huang; Amit R Patel; Jason X-J Yuan; Victor R Gordeuk; Roberto M Lang; Joe G N Garcia; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

3.  Purinergic dysregulation in pulmonary hypertension.

Authors:  Scott H Visovatti; Matthew C Hyman; Sascha N Goonewardena; Anuli C Anyanwu; Yogendra Kanthi; Patrick Robichaud; Jintao Wang; Danica Petrovic-Djergovic; Rahul Rattan; Charles F Burant; David J Pinsky
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-20       Impact factor: 4.733

Review 4.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

Review 5.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

6.  Combined contribution of endothelial relaxing autacoides in the rat femoral artery response to CPCA: an adenosine A2 receptor agonist.

Authors:  Miroslav Radenković; Marko Stojanović; Radmila Janković; Mirko Topalović; Milica Stojiljković
Journal:  ScientificWorldJournal       Date:  2012-04-19

7.  Adenosine promotes vascular barrier function in hyperoxic lung injury.

Authors:  Jonathan Davies; Harry Karmouty-Quintana; Thuy T Le; Ning-Yuan Chen; Tingting Weng; Fayong Luo; Jose Molina; Bhagavatula Moorthy; Michael R Blackburn
Journal:  Physiol Rep       Date:  2014-09-28

Review 8.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.